Clin Exp Vaccine Res.  2015 Jul;4(2):195-199. 10.7774/cevr.2015.4.2.195.

Adverse reactions to Mycobacterium bovis bacille Calmette-Guerin vaccination against tuberculosis in Iranian children

• Mahmoudi S
• Khaheshi S
• Pourakbari B
• Aghamohammadi A
• Keshavarz Valian S
• Bahador A
• Sabouni F
• Ramezani A
• Mamishi S

• KMID: 1965405
• DOI: http://doi.org/10.7774/cevr.2015.4.2.195

Abstract

PURPOSE
There are considerable variations in the number of adverse reaction reports related to vaccine from different countries. The aim of this study was to review the development of adverse reactions to bacille Calmette-Guerin (BCG) vaccination among hospitalized patients in an Iranian referral hospital.
MATERIALS AND METHODS
We identified hospitalized patients with BCG complications in Pediatric Infectious Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran during January 2007-April 2009. Data on demographics, clinical features, laboratory findings, personal history (including vaccination history), family history, and outcomes were retrieved from medical records.
RESULTS
There were 46 cases with BCG complication during the 2 years period. All of the children received vaccination at birth. Twenty-eight patients (61%) were male. The mean age of the patients was 13.5 +/-11.3 months (range, 1 to 52 months; median, 10 months). The majority of children (57%) with BCG complication were less than 1 year old. Among hospitalized patients due to BCG complications, suppurative lymphadenitis was occurred in 28 children (61%) and lymphadenopathy was seen in 9 children (20%). Disseminated BCG was detected in 8 patients (17%) and only 1 child (2%) was presented with abscess. In 7% (n = 3) of children, the family history of BCG complications were positive.
CONCLUSION
The most common side effect of the BCG vaccine in our study was suppurative lymphadenitis. Disseminated BCG infection in complications leading to hospitalization in our study was 17%. With regard to the difficulty in implementing such a guideline in settings where BCG is given to all newborns, registration of Iranian primary immunodeficiency disorders (PID) patients would be helpful to increase the awareness of medical community of Iran to investigate underlying disease. In addition, BCG vaccination should postpone in each newborn with a family history of PID until the definite condition has been ruled out.

Keyword

Bacille Calmette-Guerin; Complication; Children

MeSH Terms

Abscess
BCG Vaccine
Child*
Communicable Diseases
Demography
Hospitalization
Humans
Infant, Newborn
Iran
Lymphadenitis
Lymphatic Diseases
Male
Medical Records
Mycobacterium bovis*
Mycobacterium*
Parturition
Referral and Consultation
Tuberculosis*
Vaccination*
BCG Vaccine

Reference

1. Rezai MS, Khotaei G, Mamishi S, Kheirkhah M, Parvaneh N. Disseminated bacillus Calmette-Guerin infection after BCG vaccination. J Trop Pediatr. 2008; 54:413–416.

2. Daei Parizi M, Kardoust Parizi A, Izadipour S. Evaluating clinical course of BCG lymphadenitis and factors affect on it during a 5-year period in Kerman, Iran. J Trop Pediatr. 2014; 60:148–153.

3. Murphy D, Corner LA, Gormley E. Adverse reactions to Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccination against tuberculosis in humans, veterinary animals and wildlife species. Tuberculosis (Edinb). 2008; 88:344–357.

4. Bolger T, O'Connell M, Menon A, Butler K. Complications associated with the bacille Calmette-Guerin vaccination in Ireland. Arch Dis Child. 2006; 91:594–597.

5. Govindarajan KK, Chai FY. BCG Adenitis-need for increased awareness. Malays J Med Sci. 2011; 18:66–69.

6. Lotte A, Wasz-Hockert O, Poisson N, et al. Second IUATLD study on complications induced by intradermal BCG-vaccination. Bull Int Union Tuberc Lung Dis. 1988; 63:47–59.

7. Afshar Paiman S, Siadati A, Mamishi S, Tabatabaie P, Khotaee G. Disseminated Mycobacterium bovis infection after BCG vaccination. Iran J Allergy Asthma Immunol. 2006; 5:133–137.

8. Marciano BE, Huang CY, Joshi G, et al. BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies. J Allergy Clin Immunol. 2014; 133:1134–1141.

9. Goraya JS, Virdi VS. Bacille Calmette-Guerin lymphadenitis. Postgrad Med J. 2002; 78:327–329.

10. Sharifi Asadi P, Aghamohammadi A, Mahmoudi S, Pourakbari B, Saboui F, Mamishi S. Clinical, laboratory and imaging findings of the patients with disseminated bacilli Calmette-Guerin disease. Allergol Immunopathol (Madr). 2015; 43:254–258.

11. FitzGerald JM. Management of adverse reactions to bacille Calmette-Guerin vaccine. Clin Infect Dis. 2000; 31:Suppl 3. S75–S76.

12. Bukhari E, Alzahrani M, Alsubaie S, Alrabiaah A, Alzamil F. Bacillus Calmette-Guerin lymphadenitis: a 6-year experience in two Saudi hospitals. Indian J Pathol Microbiol. 2012; 55:202–205.

13. Turnbull FM, McIntyre PB, Achat HM, et al. National study of adverse reactions after vaccination with bacille Calmette-Guerin. Clin Infect Dis. 2002; 34:447–453.

14. Sadeghi-Shanbestari M, Ansarin K, Maljaei SH, et al. Immunologic aspects of patients with disseminated bacille Calmette-Guerin disease in north-west of Iran. Ital J Pediatr. 2009; 35:42.

15. Jeena PM, Chhagan MK, Topley J, Coovadia HM. Safety of the intradermal Copenhagen 1331 BCG vaccine in neonates in Durban, South Africa. Bull World Health Organ. 2001; 79:337–343.

16. Talbot EA, Perkins MD, Silva SF, Frothingham R. Disseminated bacille Calmette-Guerin disease after vaccination: case report and review. Clin Infect Dis. 1997; 24:1139–1146.

17. Al-Hajoj S, Memish Z, Abuljadayel N, AlHakeem R, AlRabiah F, Varghese B. Molecular confirmation of bacillus Calmette Guerin vaccine related adverse events among Saudi Arabian children. PLoS One. 2014; 9:e113472.

18. Norouzi S, Aghamohammadi A, Mamishi S, Rosenzweig SD, Rezaei N. Bacillus Calmette-Guerin (BCG) complications associated with primary immunodeficiency diseases. J Infect. 2012; 64:543–554.

19. Parvaneh N, Pourakbari B, Rezaei N, et al. Impaired in-vitro responses to IL-12 and IFN-gamma in Iranian patients with Mendelian susceptibility to mycobacterial disease. Allergol Immunopathol (Madr). 2014; 09. 05. [Epub]. DOI: 10.1016/j.aller.2014.05.008.

20. Aghamohammadi A, Mohammadinejad P, Abolhassani H, et al. Primary immunodeficiency disorders in Iran: update and new insights from the third report of the national registry. J Clin Immunol. 2014; 34:478–490.

21. Roxo-Junior P, Silva J, Andrea M, et al. A family history of serious complications due to BCG vaccination is a tool for the early diagnosis of severe primary immunodeficiency. Ital J Pediatr. 2013; 39:54.

22. Santos A, Dias A, Cordeiro A, et al. Severe axillary lymphadenitis after BCG vaccination: alert for primary immunodeficiencies. J Microbiol Immunol Infect. 2010; 43:530–537.